Cision PR Newswire

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk...

2025 Blancpain-Imaginist Literary Prize Now Accepting Submissions

BEIJING, April 23, 2025 /PRNewswire/ -- On April 15, 2025, the eighth Blancpain – Imaginist Literary Prize was officially launched. From now until May...

International Forum on Northeast China Impressions: The Local-Cosmopolitan Dimensions of Northeast China’s Culture Held at Jilin University

BEIJING, April 23, 2025 /PRNewswire/ -- A report from China Daily: On April 18th, the International Forum on Northeast China Impressions: The Local-Cosmopolitan Dimensions...

Baozun Releases 2024 Sustainability Report

SHANGHAI, April 23, 2025 /PRNewswire/ -- Baozun Inc. (Nasdaq: BZUN and HKEX: 9991) ("Baozun", "we" or the "Company"), a leading brand e-commerce solution provider...